In summary, these results indicate that cabozantinib treatment in patients with ccRCC induces high CD8+ T cells in tumors, and importantly increases the presence of TCF1+ stem-like CD8+ T cells. This evidence concerns the gene CD8A and nonpapillary renal cell carcinoma.